Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 22, 2019

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Crohn Disease
Interventions
DRUG

5-aminolevulinic acid

5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour

PROCEDURE

Blue light photopheresis

The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.

PROCEDURE

Transfusion

The treated cells are transferred back to the patient as a standard blood transfusion

PROCEDURE

Continuous Mononuclear Cell Collection (CMNC)

The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.

Trial Locations (1)

1478

Akershus University Hospital, Lorenskog

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

lead

University Hospital, Akershus

OTHER

NCT04164849 - Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid | Biotech Hunter | Biotech Hunter